Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy

NCT04154787 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

37

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Idiopathic Membranous Nephropathy

Interventions

DRUG: LNP023
DRUG: Rituximab

Sponsor

Novartis Pharmaceuticals